Screener
Revolution Medicines, Inc. RVMD Total Revenue
Discontinued — last reported Q4 '25
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Revolution Medicines, Inc.’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:11 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-071563
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Revenue: | |||
| Collaboration revenue | — | — | $11,580 |
| Total revenue | — | — | 11,580 |
| Operating expenses: | |||
| Research and development | 987,332 | 592,225 | 423,144 |
| General and administrative | 195,037 | 97,299 | 75,621 |
| Total operating expenses | 1,182,369 | 689,524 | 498,765 |
| Loss from operations | (1,182,369) | (689,524) | (487,185) |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Revolution Medicines, Inc.'s total revenue?
- Revolution Medicines, Inc. (RVMD) reported total revenue of $0 in Q4 2025.
- What is the long-term trend for Revolution Medicines, Inc.'s total revenue?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $29.39M to $0.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Revolution Medicines, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude